|
May 28
|
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program
|
|
May 23
|
Exploring High Growth Tech Stocks In The US May 2025
|
|
May 8
|
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic ...
|
|
May 8
|
Q1 2025 Geron Corp Earnings Call
|
|
May 7
|
Why Geron Stock Crept Higher Today
|
|
May 7
|
Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 7
|
Geron: Q1 Earnings Snapshot
|
|
May 7
|
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights
|
|
Mar 11
|
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
|
|
Mar 11
|
Geron Corporation Announces Departure of Chief Executive Officer
|
|
Mar 1
|
Analysts Just Shaved Their Geron Corporation (NASDAQ:GERN) Forecasts Dramatically
|
|
Feb 27
|
We Think Geron (NASDAQ:GERN) Can Afford To Drive Business Growth
|
|
Feb 27
|
Geron Corp (GERN) Q4 2024 Earnings Call Highlights: Strong Cash Position and Rytelo's FDA ...
|
|
Feb 27
|
Q4 2024 Geron Corp Earnings Call
|
|
Feb 26
|
Why Geron Stock Is Plummeting Today
|
|
Feb 26
|
Geron (GERN) Q4 2024 Earnings Call Transcript
|
|
Feb 26
|
Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 26
|
Geron: Q4 Earnings Snapshot
|
|
Feb 26
|
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
|
|
Feb 21
|
Geron to Participate at Upcoming Investor Conferences in March 2025
|